SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: david nordic who wrote (374)3/8/2006 10:02:12 AM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 447
 
Its too early to call.

The guidance cut already happened. More important than the cut in revenue guidance is the revelation that OSIP won’t be profitable even by 4Q06. Clearly, their costs are out of line with anticipated revenues. Disclosure: short at 31.66 (http://www.investorshub.com/boards/read_msg.asp?message_id=9957762 )


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News